Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03652610
Registration number
NCT03652610
Ethics application status
Date submitted
28/08/2018
Date registered
29/08/2018
Date last updated
9/02/2021
Titles & IDs
Public title
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
Query!
Scientific title
Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age
Query!
Secondary ID [1]
0
0
V59_71
Query!
Secondary ID [2]
0
0
205343
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Infections, Meningococcal
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Other interventions - Licensed GSK MenACWY vaccine (Menveo)
Experimental: GSK3536820A ACWY_Liq Group - Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
Active Comparator: ACWY Group - Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
Other interventions: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
Other interventions: Licensed GSK MenACWY vaccine (Menveo)
Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group, and Between-group Ratios
Query!
Assessment method [1]
0
0
hSBA titers against N.meningitidis serogroup A were calculated in terms of GMTs adjusted for pre-vaccination titer.
Query!
Timepoint [1]
0
0
At Day 29
Query!
Secondary outcome [1]
0
0
hSBA GMTs Against Each of the N.Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Ratios
Query!
Assessment method [1]
0
0
hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroups A, C, W and Y.
Query!
Timepoint [1]
0
0
At Day 1 and Day 29
Query!
Secondary outcome [2]
0
0
Within-group Geometric Mean Ratios (GMRs) Against Each of the N.Meningitidis Serogroups A, C, W and Y
Query!
Assessment method [2]
0
0
Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.
Query!
Timepoint [2]
0
0
At Day 29
Query!
Secondary outcome [3]
0
0
Percentages of Subjects With a =4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group, and Between-group Differences
Query!
Assessment method [3]
0
0
The percentages of subjects with a = 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs were computed by group and for each N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: for individuals, whose pre-vaccination titers are < the LOD (limit of detection), the post-vaccination titers must be = 4-fold the LOD or = the LLOQ (lower of limit of quantitation) whichever is greater; for individuals, whose pre-vaccination titers are = the LOD and = the LLOQ, the post-vaccination titers must be at least four times the LLOQ; for individuals whose pre-vaccination titers are > the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination
Query!
Timepoint [3]
0
0
At Day 29
Query!
Secondary outcome [4]
0
0
Percentages of Subjects With hSBA Titers =8 Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences
Query!
Assessment method [4]
0
0
For each vaccine group the percentage of subjects with hSBA titer =8, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.
Query!
Timepoint [4]
0
0
At Day 1 and Day 29
Query!
Secondary outcome [5]
0
0
Percentages of Subjects With hSBA Titers =LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences
Query!
Assessment method [5]
0
0
For each vaccine group the percentage of subjects with hSBA titer =LLOQ, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.
Query!
Timepoint [5]
0
0
At Day 1 and Day 29
Query!
Secondary outcome [6]
0
0
Number of Subjects Reported With Solicited Local and Systemic AEs
Query!
Assessment method [6]
0
0
Number of subjects with solicited local and systemic AEs during the 7-days period (including the day of vaccination) after the vaccination.
Query!
Timepoint [6]
0
0
From Day 1 (6 hours) to Day 7 after vaccination
Query!
Secondary outcome [7]
0
0
Number of Subjects Reported With Other Indicators of Reactogenicity
Query!
Assessment method [7]
0
0
Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after vaccination
Query!
Timepoint [7]
0
0
From Day 1 to Day 7 after vaccination
Query!
Secondary outcome [8]
0
0
Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination
Query!
Assessment method [8]
0
0
An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
Query!
Timepoint [8]
0
0
From Day 1 to Day 29 after vaccination
Query!
Secondary outcome [9]
0
0
Number of Subjects Reported With AEs Leading to Withdrawal, Medically Attended AEs and Serious Adverse Events (SAEs)
Query!
Assessment method [9]
0
0
Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity
Query!
Timepoint [9]
0
0
From Day 1 to Day 181 (during the entire study period)
Query!
Secondary outcome [10]
0
0
Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination
Query!
Assessment method [10]
0
0
An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
Query!
Timepoint [10]
0
0
Within 30 minutes after vaccination at Day 1
Query!
Eligibility
Key inclusion criteria
1. Subjects who, in the opinion of the investigator, can and will comply with the
requirements of the protocol or subjects' parent(s)/Legally Acceptable
Respresentative(s) [LAR(s)] who, in the opinion of the investigator, can and will
comply, with the requirements of the protocol.
2. Written informed consent obtained from the subject/from the parents(s)/LAR(s) of the
subject prior to performance of any study specific procedure.
3. Written informed assent obtained for subjects below legal age of consent, if required
by local regulations, at the time of enrolment.
4. A male or female between, and including, =18 to =40 YoA at the time of the first
vaccination.
5. Healthy subjects as established by medical history and clinical examination before
entering into the study.
6. Female subjects of non-childbearing potential may be enrolled in the study.
- Non-childbearing potential is defined as pre-menarche, current bilateral tubal
ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
7. Female subjects of childbearing potential may be enrolled in the study, if the
subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period.
(approximately 1 month after vaccination).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
40
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Anaphylaxis following the administration of vaccine
2. Any (clinical) condition that in the judgment of the investigator would make
intramuscular injection unsafe and/or represents a contraindication to intramuscular
vaccination and blood draws.
3. Any confirmed or suspected immunosuppressive or immunodeficient condition, including
HIV infection.
4. Progressive, unstable or uncontrolled clinical conditions.
5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products
or medical equipment whose use is foreseen in this study.
6. Hypersensitivity to the active substances or to any of the excipients of the vaccine,
including diphtheria toxoid (CRM197), or a life-threatening reaction after previous
administration of a vaccine containing similar components.
7. Abnormal function of the immune system resulting from:
- Clinical conditions.
- Systemic administration of corticosteroids (Per os [PO]/ Intravenous [IV]/
Intramuscular [IM]) for more than 14 consecutive days within 90 days prior to
informed consent, and until the Day 29 blood draw.
- Administration of antineoplastic and immuno-modulating agents or radiotherapy
within 90 days prior to informed consent, and until the Day 29 blood draw.
8. Received immunoglobulins or any blood products within 180 days prior to informed
consent.
9. Received an investigational or non-registered medicinal product within 30 days prior
to informed consent.
10. Any other clinical condition that, in the opinion of the investigator, might interfere
with the results of the study or pose additional risk to the subject due to
participation in the study.
11. History of any meningococcal vaccination.
12. Individuals who received any other vaccines within 7 days (for inactivated vaccines)
or 14 days (for live vaccines) prior to enrolment in this study or who are planning to
receive any vaccine within 28 days from the study vaccines*.
* In case an emergency mass vaccination for an unforeseen public health threat (e.g.:
a pandemic) is organised by the public health authorities, outside the routine
immunization program, the time period described above can be reduced if necessary for
that vaccine provided it is licensed and used according to its Summary of Product
Characteristics (SmPC) or Prescribing Information and according to the local
governmental recommendations and provided a written approval of the Sponsor is
obtained.
13. Administration of long-acting immune-modifying drugs at any time during the study
period (e.g. infliximab).
14. Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational vaccine/product. (pharmaceutical product or device).
15. Current or previous, confirmed or suspected disease caused by N. meningitidis.
16. Household contact with and/or intimate exposure to an individual with any laboratory
confirmed N. meningitidis infection within 60 days prior to study vaccination.
17. Acute disease and/or fever within 3 days prior to study vaccination. Note: enrolment
may be postponed/delayed until such transient circumstances have ended.
- Fever is defined as body temperature = 38.0°C / 100.4°F. The preferred location
for measuring temperature in this study will be the oral cavity.
- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
infection) without fever may be enrolled at the discretion of the investigator.
18. Received systemic antibiotic treatment within 3 days prior to study vaccination or
blood draw.
19. Study personnel as an immediate family or household member.
20. Pregnant or lactating women.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/09/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/06/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
996
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Blacktown
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Kanwal
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Gold Coast
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Sherwood
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
2259 - Kanwal
Query!
Recruitment postcode(s) [3]
0
0
4222 - Gold Coast
Query!
Recruitment postcode(s) [4]
0
0
4075 - Sherwood
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [8]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Gent
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Leuven
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
British Columbia
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Nova Scotia
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Ontario
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Quebec
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Bayern
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Nordrhein-Westfalen
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Rheinland-Pfalz
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Hamburg
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Abruzzo
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Liguria
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Conegliano - Treviso
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Massafra (TA)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by
meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more
than 60 countries.
The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY
vaccine with the investigational MenACWY liquid vaccine.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03652610
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03652610
Download to PDF